Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease.

Autor: Khanna D; Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA., Evnin LB; Scleroderma Research Foundation, San Francisco, CA, USA., Assassi S; Division of Rheumatology, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA., Benton WW; Scleroderma Research Foundation, San Francisco, CA, USA.; Eicos Sciences, San Mateo, CA, USA., Gordon G; Scleroderma Research Foundation, San Francisco, CA, USA., Maslova K; Sanofi, Cambridge, MA, USA., Steffgen J; Therapeutic Area Inflammation Medicine, Boehringer Ingelheim International GmbH, Biberach, Germany., Maher TM; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.; National Heart and Lung Institute, Imperial College London, London, UK.

Publikováno v: Journal of scleroderma and related disorders [J Scleroderma Relat Disord] 2024 Nov 05, pp. 23971983241278079. Date of Electronic Publication: 2024 Nov 05.

Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry.

Autor: Castelino FV; Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., VanBuren JM; Department or Pediatrics, University of Utah, Salt Lake City, Utah, USA., Startup E; Department or Pediatrics, University of Utah, Salt Lake City, Utah, USA., Assassi S; The University of Texas Health Science Center at Houston, Houston, Texas, USA., Bernstein EJ; Division of Rheumatology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA., Chung L; Division of Rheumatology, Department of Medicine and Dermatology, Stanford University and Palo Alto Veterans Affairs Health Care System, Stanford, California, USA., Correia C; Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Evnin LB; Scleroderma Research Foundation, San Francisco, California, USA., Frech TM; Division of Rheumatology, Department of Internal Medicine, University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, Utah, USA., Gordon JK; Hospital for Special Surgery, New York, New York, USA., Hant FN; Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA., Hummers LK; Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Khanna D; University of Michigan Scleroderma Program, Ann Arbor, Michigan, USA., Sandorfi N; Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Shah AA; Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Shanmugam VK; Division of Rheumatology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA., Steen V; Georgetown University School of Medicine, Washington, District of Columbia, USA.

Publikováno v: International journal of rheumatic diseases [Int J Rheum Dis] 2022 Feb; Vol. 25 (2), pp. 163-174. Date of Electronic Publication: 2021 Nov 28.

Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry.

Autor: Shanmugam VK; Division of Rheumatology, The George Washington University School of Medicine and Health Sciences, 2300 M Street, NW, Room 307, Washington, DC, 20007, USA. vshanmugam@mfa.gwu.edu., Frech TM; Division of Rheumatology, Department of Internal Medicine, University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, USA., Steen VD; Division of Rheumatology, Georgetown University Medical Center, Washington, DC, USA., Hummers LK; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Shah AA; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Bernstein EJ; Division of Rheumatology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA., Khanna D; Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA., Gordon JK; Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA., Castelino FV; Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Chung L; Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine and Palo Alto Veterans Affairs Health Care System, Palo Alto, CA, USA., Hant FN; Division of Rheumatology and Immunology, Medical University of South Carolina, Charleson, SC, USA., Startup E; Department of Pediatrics, University of Utah, Salt Lake City, UT, USA., VanBuren JM; Department of Pediatrics, University of Utah, Salt Lake City, UT, USA., Evnin LB; Scleroderma Research Foundation, San Francisco, CA, USA., Assassi S; Division of Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, USA.

Publikováno v: Clinical rheumatology [Clin Rheumatol] 2020 Jan; Vol. 39 (1), pp. 93-102. Date of Electronic Publication: 2019 Oct 30.